The Smartest Way to Check Your Heart

The non-invasive test reliably detects life-threatening narrowing of the coronary arteries (coronary artery disease), the main cause of heart attacks, and provides safety for both physician and patient.

The Cardio Explorer® briefly explained

Play video

Every year, 48,000 working years are lost due to acute myocardial infarction. The risk continues to rise due to demographic trends and increasing everyday stress - but it often goes unrecognized due to the lack of or unspecific symptoms.

45% of all heart attack sufferers are asymptomatic

For some patients, the first sign is sudden death. The German Society of Cardiology (DGK) therefore calls for annual screening for all people over the age of 50.

2 out of 3 women who die of a heart attack had no symptoms

Women and people with diabetes often lack the classic symptoms.

Demographic trends increase the risk of heart attacks in the workforce

The increase in CHD-related hospital admissions among men aged 45 to 50 is a particularly worrying development.

The body releases more stress hormones such as adrenaline and inflammatory messengers, which cause the cardiovascular system to age prematurely.
Constriction in the coronary arteries
The coronary arteries constrict, which impairs blood flow. This increases the risk of heart problems such as a heart attack or heart failure.
Screening for coronary heart disease has been shown to improve the health behavior of the workforce, leading to positive lifestyle changes.
The Cardio Explorer in comparison
Stress ECG
Cardio Explorer
Computed Tomography (CT)
Physical stress
Blood collection
Radiation exposure
45 minutes
15 minutes
60 minutes
*Sensitivity: How many sick people are correctly identified. Specificity: How many healthy people are correctly detected.

"Exploris' eDiagnostic Services will transform existing processes in today's medical care for the benefit of patients. The team's close collaboration with senior physicians at leading hospitals is impressive and reflects our culture of co-creation."

Marianne Janik

CEO Microsoft Germany

"We believe Cardio Explorer, Exploris Health's innovative cardiac test, will significantly improve care for patients with suspected coronary artery disease."

Dr. Thomas M. Helms

Chairman of the Board of the German Foundation for the Chronically Ill

"Thanks to artificial intelligence, we finally have a tool that can meet the high demands in primary diagnostics."

E. Schönmann, MD

Specialist FMH for General Internal Medicine

"Artificial intelligence has become an indispensable part of modern medicine. It can be used to answer complex questions, as with Cardio Explorer, and ideally to avoid unnecessary examinations. The quality of medicine is thus increased, while the burden on patients is reduced."

Prof. Dr. med. Markus Béchir

Specialist FMH for General Internal Medicine

Clinical development & corporate health
Prof. Michael ZellwegerProf. Michael Zellweger

Prof. Michael Zellweger

Head of Noninvasive Cardiology, University Hospital Basel

Prof. Hans-Peter BrunnerProf. Hans-Peter Brunner

Prof. Hans-Peter Brunner

Prof. for Cardiology at the Medical Center, University Hospital Maastricht

Prof. Dr. med. Winfried MärzProf. Dr. med. Winfried März

Prof. Dr. med. Winfried März

Director of the SYNLAB Academy and Professor at the Clinical Institute for Medical and Chemical Laboratory Diagnostics, University of Graz, Austria.

Prof. Dr. Volker NürnbergProf. Dr. Volker Nürnberg

Prof. Dr. Volker Nürnberg

Professor of Health Management at Allensbach University of Applied Sciences.

Team in detail

Registration Cardio Explorer® Check-Up*

Find test center
*The price depends on the service level and is determined by the medical professional.
Advantages for medical professionals

Highest accuracy
(AUC of 0.87)

With an Area Under The Curve (AUC) of 0.87, the Cardio Explorer has an accuracy comparable to the best imaging techniques.

No process adjustment necessary

Cardio Explorer calculates the pre-test probability required by medical guidelines (ESC 2019) with higher precision than existing methods.

Risk stratification:
Relieving the burden of care.

Cardio Explorer enables precise risk stratification of patients with suspected CHD. This conserves scarce specialist resources and treats patients efficiently.

Certification (EMA, Swissmedic)

The Cardio Explorer is approved in Switzerland and all EU countries.

Broad validation in high and low prevalence populations.

The Cardio Explorer has been validated in three clinical studies with over 4,500 patients, in high and low prevalence populations and showed an enormously high accuracy (AUC of 0.87) in all studies. The broad validation is a prerequisite for use in primary diagnostics and prevention.

Personalized medicine

CHD reflects a system-wide and highly complex pathophysiology that requires a comprehensive combinatorial assessment of all risk factors. Artificial intelligence (AI) allows efficient and personalized assessment.

Reliable and simple risk assessment

Thanks to its simple procedure, the 15-minute Cardio Explorer® check-up can be carried out anywhere and shows whether preventive measures or further examinations are advisable.

Process of reliable individual risk assessment thanks to the Cardio Explorer® using a blood sample, blood pressure measurement and questions about current habits

The result is available immediately after entering all factors:

No further clarification
Stenosis risk <5%
Non-invasive clarification recommended
Stenosis risk ~20%
Non-invasive clarification recommended
Stenosis risk ~50%
Non-invasive workup strongly recommended, consider invasive workup
Stenosis risk >75%
Cardio Explorer Web Portal

The Cardio Explorer® can be used without additional infrastructure.

Price per application
Secure web solution
High precision
(AUC 0.87)
No device required
Easy handling
Patient data are protected
Without software installation
No special factors required

Registration Cardio Explorer® Check-Up*

Find test center
*The price depends on the service level and is determined by the medical professional.

Ischemia prediction by Cardioexplorer (SDS ≥2 (3%myocardium) on PET) subgroup analyses based on data published in the EPMA paper, 2023;14:631-643


Artificial intelligence to improve ischemia prediction in Rubidium Positron Emission Tomography-a validation study


Cardio News 27.10.2023: "The right diagnostics at the right time"


Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort.


A new non-invasive diagnostic tool in coronary artery disease: artificial intelligence as an essential element of predictive, preventive, and personalized medicine.


A new memetic pattern based algorithm to diagnose/exclude coronary artery disease.